Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07661966 · ClinicalTrials.gov registry record · NA

Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade

A NA study, sponsored by Weill Medical College of Cornell University.

Not yet
Registry status
NA
Development phase
12
Enrollment target

NCT07661966 is a NA study that has not yet begun recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07661966, a NA study, has not yet begun recruiting, sponsored by Weill Medical College of Cornell University.

NOT YET RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target

Study Summary

This study is being done to test whether bright light therapy can be used to synchronize patients' circadian rhythms and allow ICB (immune-checkpoint blockade) therapy to be administered at a time in the circadian rhythm that optimizes clinical outcomes. This trial will test the feasibility of delivering bright light therapy (BLT) to patients undergoing ICB therapy. This trial asks participants to spend 60 minutes every morning receiving daily bright light therapy for at least 7 days prior to starting Immune Checkpoint blockade-containing regimens (e.g. anti-PD-1 and/or anti-CTLA-4 alone or in combination with chemotherapy). The bright light therapy will be delivered via the Circadian OS iPad application. There is evidence that a person's circadian rhythm can affect the response to immunotherapy. The circadian rhythm is a natural, internal process that regulates the sleep-wake cycle. Many patients with cancer have disrupted circadian rhythms and it's possible that disrupted circadian rhythms decrease the likelihood of responding to immunotherapy. The idea is to use bright light therapy, delivered via the Circadian OS iPad application, for an hour in the morning to synchronize your circadian rhythm for a week before your planned immunotherapy. The investigators hope that this will increase the likelihood of a response to immunotherapy, however in this study, the investigators are mainly concerned with whether the bright light therapy is tolerable to patients.

Interventions

  • DEVICE Bright Light Therapy

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2026-06
Est. Completion 2027-12
Phase NA

What the Registry Record Tells You About NCT07661966

The ClinicalTrials.gov registry entry for NCT07661966 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Bright Light Therapy is the first listed.

NCT07661966 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07661966 about?

NCT07661966 is a clinical study titled "Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade". This study is being done to test whether bright light therapy can be used to synchronize patients' circadian rhythms and allow ICB (immune-checkpoint blockade) therapy to be administered at a time in the circadian rhythm that optimizes clinical outcomes. This trial will test the feasibility of deliv...

What is the current status of trial NCT07661966?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2026-06. Estimated completion is 2027-12.

What interventions are being tested in trial NCT07661966?

The interventions under investigation include: Bright Light Therapy (DEVICE).

Who is sponsoring clinical trial NCT07661966?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.